الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 71 |  |  |
| | | from | 71 | | |
Abstract
Breast cancer (BC) is the most common malignancy in females worldwide. It constitutes 38.8% of all malignant tumors among Egyptian females. Triple negative breast cancer hasn’t confirmed therapeutic molecular target and has a poor prognosis, so identification of new biological key pathways might aid in finding targets of potential interest for therapeutic blockade. Glucose transporter 1 (GLUT-1) has important role in the transport of glucose in malignant cells and overexpressed in different types of human cancers
The aim of this Study: to evaluate the effect of GLUT-1 on progression free survival and other clinicopathological features in breast carcinoma in Egyptian patients.
Materials and Methods: This is prospective study that included 79 invasive duct carcinoma (IDC) patients treated in clinical oncology department faculty of medicine, Menoufia University, Egypt, from the period between January, 2016 and December, 2017. All cases were stained for GLUT-1 antibody.
Results: Eighty percent of the studied IDC cases showed positive GLUT-1 expression. There was a highly statistical significant association between positive GLUT-1 expression and advanced nodal stage (P= 0.001).
Furthermore, there was a highly statistical significant association between positive GLUT-1 expression and poor degree of differentiation (Grade III) (P= 0.002). Moreover, There was a statistical significant association between GLUT-1 positivity and advanced stage (3 and 4) (P= 0.016).
Conclusion: Glucose transporter 1 (GLUT1) is a poor prognostic marker in view of association between positive GLUT-1 expression and advanced nodal stage, advanced stage grouping (III and IV) and poor degree of differentiation (Grade).Furthermore, inhibition of GLUT-1 might play a therapeutic role for breast cancer.